


# Medicxi to invest up to €40m in new collaboration based on our orexin agonist program

Highly innovative structure to accelerate value creation




Innovative deal structure provides us with ongoing revenue streams, shifts R&D costs and risk away and enables us to maintain upside via our equity stake

<sup>1</sup> Includes 10.00% shareholding allocated to employee share options

# Medicxi to invest up to €40m in new collaboration based on our orexin agonist program

*Highly innovative structure to accelerate value creation*



Innovative deal structure provides us with ongoing revenue streams, shifts R&D costs and risk away and enables us to maintain upside via our equity stake

<sup>1</sup> Includes 10.00% shareholding allocated to employee share options